Zydus Lifesciences Gets Tentative Approval From USFDA For BP Lowering Drug

Zydus Lifesciences on Thursday said it has received tentative approval from the US health regulator to market its generic Azilsartan Medoxomil tablets used to treat high blood pressure.

The tentative approval by the US Food and Drug Administration (USFDA) is for Azilsartan Medoxomil tablets of strengths 40 mg and 80 mg, Zydus Lifesciences said in a regulatory filing.

Read Also

Zydus Receives Final Approval From The USFDA For Lacosamide Tablets

Azilsartan is indicated for the treatment of hypertension to lower blood pressure and reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions, it added. |

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, it added.

Read Also

Zydus Wellness Net Profit Up 3.44% To ₹150.3 Cr In Q4FY24

Azilsartan is indicated for the treatment of hypertension to lower blood pressure and reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions, it added.

FPJ Shorts

CM Devendra Fadnavis To Unfurl Tricolour On Republic Day As Governor Acharya Devvrat Handles Dual Charge In Maharashtra And Gujarat

Western Railway Announces Three Pairs Of Weekly Superfast Special Trains To Clear Passenger Rush on Key Routes

Central Railway Honours 98 Employees, Bhusaval & Nagpur Divisions Bag Overall Efficiency Shield At 70th Vishisht Rail Seva Puraskar

NMMC Hosts Cultural, Literary Events To Celebrate Marathi Language Conservation Fortnight In Navi Mumbai

The medicine can be used either alone or in combination with other antihypertensive agents, the company said. | File/ Representative image

The medicine can be used either alone or in combination with other antihypertensive agents, the company said.

It had annual sales of USD 89 million in the US, the company said citing IQVIA March 2024 data.